Monday, July 11, 2011
SpringLeaf Therapeutics Inc., of Boston, secured an additional $4 million in a second closing of its Series B financing from new investor Excel Venture Management, bringing the total round to $19 million. The company is developing a technology designed to expand the availability of biologic therapeutics.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.